Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies
Biology · 02.10.2023 · 12 (10) · 1301
DOI: 10.3390/biology12101301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 02.10.2023. Verfasst von Amit K Dey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Geroproteomics Unit, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224,…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institute on Aging (NIA).
Abstract (Originalsprache)
Cellular senescence is a state of irreversible growth arrest with profound phenotypic changes, including the senescence-associated secretory phenotype (SASP). Senescent cell accumulation contributes to aging and many pathologies including chronic inflammation, type 2 diabetes, cancer, and neurodegeneration. Targeted removal of senescent cells in preclinical models promotes health and longevity, suggesting that the selective elimination of senescent cells is a promising therapeutic approach for mitigating a myriad of age-related pathologies in humans. However, moving senescence-targeting drugs (senotherapeutics) into the clinic will require therapeutic targets and biomarkers, fueled by an improved understanding of the complex and dynamic biology of senescent cell populations and their molecular profiles, as well as the mechanisms underlying the emergence and maintenance of senescence cells and the SASP. Advances in mass spectrometry-based proteomic technologies and workflows have the potential to address these needs. Here, we review the state of translational senescence research and how proteomic approaches have added to our knowledge of senescence biology to date. Further, we lay out a roadmap from fundamental biological discovery to the clinical translation of senotherapeutic approaches through the development and application of emerging proteomic technologies, including targeted and untargeted proteomic approaches, bottom-up and top-down methods, stability proteomics, and surfaceomics. These technologies are integral for probing the cellular composition and dynamics of senescent cells and, ultimately, the development of senotype-specific biomarkers and senotherapeutics (senolytics and senomorphics). This review aims to highlight emerging areas and applications of proteomics that will aid in exploring new senescent cell biology and the future translation of senotherapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Translational Geroproteomics Unit, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
ORCID-Profile: Amit K Dey, Reema Banarjee, Mozhgan Boroumand, Delaney V Rutherford, Quinn Strassheim, Thedoe Nyunt, Bradley Olinger, Nathan Basisty
Förderung
- NIA NIH HHS
- NIH HHS
- National Institute on Aging (NIA)
- Longevity Impetus Grants
- SenNet NIH Common Fund
Zitieren
APA
Dey, A. K., Banarjee, R., Boroumand, M., Rutherford, D. V., Strassheim, Q., Nyunt, T., Olinger, B., & Basisty, N. (2023). Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies. Biology, 12(10), 1301. https://doi.org/10.3390/biology12101301
Vancouver
Dey AK, Banarjee R, Boroumand M, Rutherford DV, Strassheim Q, Nyunt T, et al. Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies. Biology. 2023;12(10):1301. doi:10.3390/biology12101301
BibTeX
@article{Dey2023,
author = {Dey, Amit K and Banarjee, Reema and Boroumand, Mozhgan and Rutherford, Delaney V and Strassheim, Quinn and Nyunt, Thedoe and Olinger, Bradley and Basisty, Nathan},
title = {Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies},
journal = {Biology},
year = {2023},
volume = {12},
number = {10},
pages = {1301},
doi = {10.3390/biology12101301}
}
EUVIMED